{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03080974",
            "orgStudyIdInfo": {
                "id": "16.1190"
            },
            "organization": {
                "fullName": "University of Louisville",
                "class": "OTHER"
            },
            "briefTitle": "Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma",
            "officialTitle": "Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "immunotherapy-and-irreversible-electroporation-in-the-treatment-of-advanced-pancreatic-adenocarcinoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2017-08-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-04-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2017-02-14",
            "studyFirstSubmitQcDate": "2017-03-08",
            "studyFirstPostDateStruct": {
                "date": "2017-03-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-16",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Robert C. Martin",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "University of Louisville"
            },
            "leadSponsor": {
                "name": "University of Louisville",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.",
            "detailedDescription": "Immunotherapy and irreversible electroporation in the treatment of advanced pancreatic adenocarcinoma. This is a Phase II study in which all patients undergoing irreversible electroporation of locally advanced pancreatic adenocarcinoma will be treated with nivolumab post-operatively."
        },
        "conditionsModule": {
            "conditions": [
                "Pancreatic Adenocarcinoma"
            ],
            "keywords": [
                "irreversible electroporation",
                "Nivolumab"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "All patients will undergo irreversible electroporation and treatment with Nivolumab",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Single Arm",
                    "type": "EXPERIMENTAL",
                    "description": "All patients undergoing irreversible electroporation will be treated with nivolumab",
                    "interventionNames": [
                        "Drug: Nivolumab",
                        "Procedure: Irreversible Electroporation"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Nivolumab",
                    "description": "Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.",
                    "armGroupLabels": [
                        "Single Arm"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Irreversible Electroporation",
                    "description": "Non-thermal ablation of tumor",
                    "armGroupLabels": [
                        "Single Arm"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and Tolerability of Combination Irreversible Electroporation and Nivolumab Treatment",
                    "description": "Adverse events and Serious adverse events will be collected",
                    "timeFrame": "Baseline thru 100 days after receiving last dose"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Progression Free Survival",
                    "description": "CT scans will be reviewed",
                    "timeFrame": "Every three months for 4 years."
                },
                {
                    "measure": "Overall Survival",
                    "description": "CT scans will be reviewed",
                    "timeFrame": "Every three months for 4 years."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \u2265 18 years if age\n* Diagnosed with stage III pancreatic cancer\n* Tumor is measurable\n* Glomerular Filtration Rate \\> 60 m/L/min/1.73 m(2)\n* Willing and able to comply with the protocol requirements\n* Able to comprehend and have signed the informed consent to participate\n\nExclusion Criteria:\n\n* Participating in another clinical trial for the treatment of cancer at time of screening\n* Are pregnant or currently breast feeding\n* Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure\n* Have non-removable implants with metal parts within 1 cm of the target lesion\n* Had a myocardial infarction within 3 months prior to enrollment",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Marilyn Donaldson, RN",
                    "role": "CONTACT",
                    "phone": "502-629-3323",
                    "email": "marilyn.donaldson@louisville.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Robert Martin, MD, PhD",
                    "affiliation": "University of Louisville",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Louisville",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077594",
                    "term": "Nivolumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1854",
                    "name": "Nivolumab",
                    "asFound": "Technique",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}